Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Lymphoma, T-Cell, Peripheral × Salvage Therapy × 1 year × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Melanoma 1 Lymphoma, T-Cell, Peripheral 1 Breast Neoplasms 1 Brain Neoplasms 1

Interventions

Cyclophosphamide 11 Prednisone 8 Doxorubicin 8 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 7 Vincristine 6 Azacitidine 5 fludarabine 4 Gemcitabine 4 Etoposide 4 Brentuximab Vedotin 4 romidepsin 3 belinostat 3 Dexamethasone 3 Biopsy 3 10-propargyl-10-deazaaminopterin 3 tazemetostat 2 ruxolitinib 2 pembrolizumab 2 Lenalidomide 2 Bendamustine Hydrochloride 2 venetoclax 1 tislelizumab 1 tipifarnib 1 thymoglobulin 1 sodium-iodide symporter 1 selinexor 1 relatlimab 1 pomalidomide 1 ixazomib 1 ivarmacitinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07470996 2026-03-13

T-START-NR

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon ⚡